The company's financial position is increasingly fragile, with equity contracting to $4.8 million in 2026Q1 from $7.2 million in 2024Q1 due to persistent operational deficits.
| Total Current Assets | 6.26M | 4.9M | 5.39M | 7.24M | 1.1M | 1.18M | 2.44M |
| Cash & Short-Term Investments | 3.34M | 2.75M | 3.39M | 2.14M | 264.87K | 115.4K | 191.7K |
| Cash Only | 3.34M | 1.51M | 1.66M | 2.14M | 264.87K | 115.4K | 191.7K |
| Short-Term Investments | 0 | 1.24M | 1.73M | 0 | 0 | 0 | 0 |
| Accounts Receivable | 335.84K | 509.64K | 486.75K | 231.33K | 45.97K | 146.36K | 859.42K |
| Days Sales Outstanding | 164.92 | 185.01 | 292.41 | 332.99 | 75.16 | 46.04 | 143.8 |
| Inventory | 910.6K | 656.92K | 442.76K | 466.17K | 518.58K | 689.04K | 1.04M |
| Days Inventory Outstanding | 332.53 | 306.74 | 420.02 | 358.55 | 437.78 | 295.62 | 539.77 |
| Other Current Assets | 1.68M | 978.13K | 1.07M | 2.73M | 68.63K | 0 | 0 |
| Total Non-Current Assets | 502.88K | 470.73K | 373.07K | 541.18K | 198.2K | 216.85K | 163.18K |
| Property, Plant & Equipment | 259.67K | 246.37K | 149.81K | 71.28K | 33.95K | 107.61K | 73.41K |
| Fixed Asset Turnover | 4.33x | 4.08x | 4.06x | 3.56x | 6.58x | 10.78x | 29.72x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 243.21K | 224.36K | 157.08K | 227.26K | 164.25K | 109.24K | 80.23K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 66.18K | 242.65K | 0 | 0 | 9.55K |
| Total Assets | 6.76M | 5.37M | 5.76M | 7.78M | 1.3M | 1.39M | 2.61M |
| Asset Turnover | 0.17x | 0.19x | 0.11x | 0.03x | 0.17x | 0.83x | 0.84x |
| Asset Growth % | -6.9% | -6.83% | -26.01% | 500.04% | -6.91% | -46.53% | - |
| Total Current Liabilities | 1.88M | 1.84M | 1.66M | 2.84M | 23.92M | 635.47K | 1.43M |
| Accounts Payable | 1.49M | 1.46M | 1.01M | 506.21K | 758.67K | 588.68K | 1.38M |
| Days Payables Outstanding | 602.56 | 681.39 | 955.86 | 389.35 | 640.46 | 252.56 | 714.95 |
| Short-Term Debt | 8.77K | 8.77K | 8.77K | 8.77K | 21.14M | 93.89K | 53.31K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 325K | 0 | 0 |
| Other Current Liabilities | 379.31K | 374.74K | 640.83K | 2.31M | 1.49M | -93.89K | -51.26K |
| Current Ratio | 3.34x | 2.66x | 3.25x | 2.55x | 0.05x | 1.85x | 1.70x |
| Quick Ratio | 2.85x | 2.30x | 2.98x | 2.39x | 0.02x | 0.77x | 0.98x |
| Cash Conversion Cycle | -105.12 | -189.64 | -243.42 | 302.19 | -127.52 | 89.1 | -31.38 |
| Total Non-Current Liabilities | 143.2K | 144K | 147.12K | 150.25K | 1.53M | 18.91M | 19.24M |
| Long-Term Debt | 143.2K | 144K | 147.12K | 150.25K | 1.27M | 18.74M | 19.14M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 13K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 255K | 154.74K | 103.01K |
| Total Liabilities | 2.02M | 1.99M | 1.8M | 2.99M | 25.45M | 19.55M | 20.68M |
| Total Debt | 151.97K | 152.78K | 155.89K | 172.67K | 22.42M | 18.8M | 19.14M |
| Net Debt | -3.19M | -1.36M | -1.5M | -1.97M | 22.15M | 18.69M | 15.73M |
| Debt / Equity | 0.03x | 0.05x | 0.04x | 0.04x | - | - | - |
| Debt / EBITDA | -0.02x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.41x | - | - | - | - | - | - |
| Interest Coverage | -1023.78x | -943.05x | -1004.49x | -0.67x | -0.55x | -0.34x | -0.14x |
| Total Equity | 4.74M | 3.38M | 3.96M | 4.8M | -24.15M | -18.15M | -18.07M |
| Equity Growth % | -44.63% | -14.55% | -17.57% | 119.87% | -33.02% | -0.46% | - |
| Book Value per Share | 2.75 | 5.04 | 34.80 | 4.85 | -16.71 | -12.56 | -12.50 |
| Total Shareholders' Equity | 4.83M | 3.46M | 4.04M | 4.87M | -23.58M | -17.58M | -17.5M |
| Common Stock | 264 | 116 | 57 | 10 | 239 | 4.98M | 799.7K |
| Retained Earnings | -49.98M | -47.89M | -40.53M | -32.58M | -28.82M | -22.63M | -18.38M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 148.54K | 142.6K | 135.47K | 135.56K | 73.71K | 75.83K | 80.45K |
| Minority Interest | -84.7K | -83.76K | -80.59K | -72.04K | -572.32K | -576.26K | -569.29K |
Imminent liquidity exhaustion
As reported in recent financial filings, SXTP's equity has contracted from $7.2 million in 2024Q1 to $4.8 million in 2026Q1, reflecting a persistent erosion of the balance sheet as the company struggles to fund its commercial operations through internal cash generation rather than external capital.
The consistent decline in retained earnings, which reached -$50.0 million by 2026Q1, underscores a business model that is currently unable to achieve self-sustaining profitability. This trajectory suggests that the company's survival is increasingly dependent on external financing, which may become more difficult to secure given the lack of clear operational scale.
Based on the company's reported figures, cash and equivalents plummeted to $1.5 million in 2025Q4 before a slight recovery to $3.3 million in 2026Q1, yet this remains insufficient to cover the high quarterly operating burn rates observed in recent historical periods.
While the current ratio of 3.34 appears superficially healthy, it is heavily influenced by the composition of current assets which may not be easily liquidated to meet immediate obligations. Investors should monitor the cash-to-burn ratio closely, as the current liquidity buffer provides little margin for error in the event of clinical or commercial delays.
According to the provided balance sheet data, the company's equity base is severely compromised by an accumulated deficit of $50.0 million as of 2026Q1, which indicates that historical capital raises have been largely consumed by operating losses rather than productive asset accumulation.
The persistent negative retained earnings suggest that the company has yet to reach a point of operational inflection where equity value can be preserved. This structure implies that future financing rounds will likely be highly dilutive to existing shareholders, as the company lacks the earnings power to support its current valuation.
As indicated by the financial statements, the company's asset base is heavily reliant on intangible assets and goodwill, which totaled $243.2K in 2026Q1, potentially masking the lack of tangible, revenue-generating infrastructure required to support the commercialization of Arakoda.
The reliance on intangible assets warrants further investigation, as these items are subject to impairment risk if the commercial performance of the company's primary product fails to meet internal projections. The lack of significant PPE growth suggests that the company is not investing in the physical capacity needed to scale production, which may limit future revenue potential.
Quick answers to the most common questions about buying SXTP stock.
As of 2025, 60 Degrees Pharmaceuticals, Inc. (SXTP) had total assets of $5.4M including $4.9M in current assets.
60 Degrees Pharmaceuticals, Inc. (SXTP) carries total debt of $0.2M, offset by $2.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
60 Degrees Pharmaceuticals, Inc. (SXTP) has total shareholders' equity (book value) of $3.5M ($5.04 book value per share). Book value represents the net worth of the company belonging to common stock holders.
60 Degrees Pharmaceuticals, Inc. (SXTP) reported a current ratio of 2.66x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.